Aligos Therapeutics, Inc. Deferred Revenue Recognized
Aligos Therapeutics, Inc. (ALGS) reported Deferred Revenue Recognized of $2.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-08-06
- Aligos Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2026-03-31 was $2.80M.
- Aligos Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-09-30 was $0.00.
- Aligos Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-06-30 was $0.00.
- Aligos Therapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $0.00.
- Aligos Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2025 was $0.00.
- Aligos Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2024 was $0.00.
- Aligos Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2023 was $0.00.
- Aligos Therapeutics, Inc. contract with customer, liability, revenue recognized for fiscal 2022 was $0.00.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.80M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $2.80M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $0.00 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-03-10 | |||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-06 | $0.00 10-Q · filed 2023-11-02 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 10-Q · filed 2023-08-03 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-03-12 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-03 | $0.00 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |